MYO (Myomo Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MYO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Milton Mayo Morris | Director | Sell | — | — |
| 2026-08-24 | Harry Kovelman | Chief Medical Officer | Sell | — | — |
| 2026-08-21 | Harry Kovelman | Chief Medical Officer | Sell | — | — |
| 2026-08-11 | Micah Mitchell | Chief Commercial Officer | MIXED | — | — |
| 2026-08-11 | DAVID A HENRY | Chief Financial Officer | MIXED | — | — |
| 2026-08-11 | PAUL R GUDONIS | Chief Executive Officer | A | — | — |
| 2026-08-11 | Harry Kovelman | Chief Medical Officer | MIXED | — | — |
| 2026-07-13 | PAUL R GUDONIS | Chief Executive Officer | A | — | — |
| 2026-07-13 | DAVID A HENRY | Chief Financial Officer | MIXED | — | — |
| 2026-06-26 | Thomas Aloysius Crowley Jr. | Director | A | — | — |
| 2026-06-26 | Joseph M. Manko Jr. | Director | A | — | — |
| 2026-06-26 | Heather C Getz | Director | A | — | — |
| 2026-06-26 | Milton Mayo Morris | Director | A | — | — |
| 2026-06-26 | WILLIAM J FEBBO | Director | A | — | — |
| 2026-06-26 | THOMAS F KIRK | Director | A | — | — |
| 2026-06-12 | DAVID A HENRY | Chief Financial Officer | F | — | — |
| 2026-06-12 | Micah Mitchell | Chief Commercial Officer | F | — | — |
| 2026-06-12 | Harry Kovelman | Chief Medical Officer | F | — | — |
| 2026-06-09 | Micah Mitchell | Chief Commercial Officer | F | — | — |
| 2026-06-09 | DAVID A HENRY | Chief Financial Officer | F | — | — |
| 2026-06-09 | THOMAS F KIRK | Director | Buy | — | — |
| 2026-06-09 | Harry Kovelman | Chief Medical Officer | F | — | — |
| 2026-06-08 | Micah Mitchell | Chief Commercial Officer | Sell | — | — |
| 2026-06-01 | THOMAS F KIRK | Director | Buy | — | — |
| 2026-05-28 | Harry Kovelman | Chief Medical Officer | Sell | — | — |
| 2026-05-18 | Joseph M. Manko Jr. | Director | Buy | — | — |
| 2026-05-18 | THOMAS F KIRK | Director | Buy | — | — |
| 2026-05-15 | Micah Mitchell | Chief Commercial Officer | Sell | — | — |
| 2026-04-16 | WILLIAM J FEBBO | Director | A | — | — |
| 2026-04-14 | DAVID A HENRY | Chief Financial Officer | MIXED | — | — |
| 2026-04-14 | PAUL R GUDONIS | Chief Executive Officer | A | — | — |
| 2026-04-14 | PAUL R GUDONIS | Chief Executive Officer | A | — | — |
| 2026-03-17 | Heather C Getz | Director | Buy | — | — |
| 2026-03-16 | THOMAS F KIRK | Director | Buy | — | — |
| 2026-03-12 | Heather C Getz | Director | Buy | — | — |
| 2026-01-14 | DAVID A HENRY | Chief Financial Officer | A | — | — |
| 2026-01-14 | PAUL R GUDONIS | Chief Executive Officer | A | — | — |
| 2025-11-24 | THOMAS F KIRK | Director | Buy | — | — |
| 2025-11-21 | Thomas Aloysius Crowley Jr. | Director | Buy | — | — |
| 2025-09-11 | PAUL R GUDONIS | Chief Executive Officer | G | — | — |
| 2025-08-26 | THOMAS F KIRK | Director | Buy | — | — |
| 2025-08-19 | THOMAS F KIRK | Director | Buy | — | — |
| 2025-08-18 | PAUL R GUDONIS | Chief Executive Officer | Buy | — | — |
| 2025-07-02 | Harry Kovelman | Chief Medical Officer | F | — | — |
| 2025-07-02 | DAVID A HENRY | Chief Financial Officer | F | — | — |
| 2025-06-13 | DAVID A HENRY | Chief Financial Officer | A | — | — |
| 2025-06-13 | PAUL R GUDONIS | Chief Executive Officer | A | — | — |
| 2025-06-13 | Micah Mitchell | Chief Commercial Officer | A | — | — |
| 2025-06-13 | Harry Kovelman | Chief Medical Officer | A | — | — |
| 2025-06-12 | Heather C Getz | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,388,479 | — |
| — | Chief Executive Officer | 1,434,679 | — |
| — | Director | 772,569 | — |
| — | Chief Financial Officer | 495,473 | — |
| — | Director | 210,458 | — |
| — | Director | 208,391 | — |
| — | Director | 154,931 | — |
| — | Chief Commercial Officer | 152,297 | — |
| — | Director | 123,704 | — |
| — | Chief Medical Officer | 105,733 | — |
| — | Director | 91,645 | — |
| — | VP, General Manager | 22,298 | — |
| — | Director | 19,021 | — |
| — | Chief Marketing Officer | 17,738 | — |
| — | Chief Financial Officer | 2,837 | — |
| — | Chief Medical Officer | 1,664 | — |
| — | VP, Sales | 1,456 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MYO quote page; the site-wide leaderboard is on the insider transactions hub.